EXEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Exelixis Inc (EXEL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial performance, positive growth trends in its core oncology market, and upcoming catalysts like regulatory approvals for Cabometyx and Zanzalintinib. Despite some neutral trading sentiment and a lack of immediate trading signals, the long-term growth potential and favorable analyst ratings make it a solid investment opportunity.
The technical indicators for EXEL are mixed but lean slightly bullish. The MACD is positive at 0.152 and contracting, suggesting a potential slowdown in momentum. RSI at 53.152 is neutral, indicating no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near a key pivot level of 44.111, with resistance at 45.456 and support at 42.767.
Strong financial performance in Q4 2025, with revenue up 5.63% YoY and net income up 74.84% YoY. EPS also increased by 83.33%.
Cabometyx remains the top-prescribed treatment for renal cell carcinoma and is expected to expand its market presence with new approvals.
Zanzalintinib has completed a phase 3 study and is seeking regulatory approval, which could drive future growth.
The global oncology market is projected to grow significantly, benefiting companies like Exelixis.
Analysts have mixed ratings, with some downgrades citing valuation concerns and limited high-impact catalysts in
Gross margin dropped slightly by -0.93% YoY, which could indicate some cost pressures.
The stock has a 60% chance of declining by -3.51% over the next month based on candlestick pattern analysis.
In Q4 2025, Exelixis reported strong financials: Revenue increased by 5.63% YoY to $598.66 million, net income surged by 74.84% YoY to $244.53 million, and EPS grew by 83.33% YoY to 0.88. However, gross margin dipped slightly to 95.58%, down -0.93% YoY.
Analysts are generally positive on EXEL, with multiple firms raising price targets recently. H.C. Wainwright raised its target to $54 and maintains a Buy rating, citing encouraging financial guidance and upcoming catalysts. However, some firms like BofA downgraded the stock to Underperform due to valuation concerns and limited high-impact catalysts in 2026. The average price target is in the $44-$54 range, suggesting moderate upside potential.
